Actively Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-01-05
100
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead Sponsor
A
Affiliated Hospital of Jiaxing University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
CONDITIONS
Official Title
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of symptomatic multiple myeloma with high-risk genetic features according to IMWG 2016 criteria
- ECOG performance status between 0 and 3
- Completed induction and consolidation of VRD regimen; for eligible patients under 65, stem cell collection and autologous transplant as planned
- Expected survival longer than 6 months
- Age between 18 and 80 years
- Adequate kidney, liver, lung, and heart function as defined by specific lab and clinical criteria
- Negative pregnancy tests for women of childbearing potential; strict contraception required if treated with lenalidomide
- Ability to comply with the study protocol
- Voluntary participation with signed informed consent
You will not qualify if you...
- Uncontrolled fungal, bacterial, viral, or other infections requiring intravenous treatment
- Known HIV infection or untreated hepatitis B or C infections
- History of thrombosis within the past 6 months
- History of malignancy other than certain in situ cancers unless disease-free for at least 3 years
- Uncontrolled heart rhythm problems or significant cardiac disease within 12 months
- Significant immunodeficiency
- Medical conditions interfering with safety or efficacy assessments
- History of severe allergic reactions to study drugs
- Pregnant or breastfeeding women of childbearing potential
- Unwillingness to use birth control during the study and for 6 months after
- Inability to complete all study visits or follow-up
- Autoimmune diseases causing organ damage or requiring systemic immunosuppressive treatment within 2 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yang Xu
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
X
Xuzhao Zhang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here